Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin Genetics Seeks to Raise $5.3M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Interleukin Genetics today said that it has received commitments from certain institutional investors to purchase $5.3 million of the firm's stock through a direct placement.

Under the agreements, Interleukin said that it will sell in aggregate 4,375,002 shares of its common stock and warrants to purchase up to 1,750,000 additional shares of common stock. Each unit will be sold for $1.20 and consist of one share of common stock and a warrant to purchase 0.40 of a share of common stock.

The warrants will be exercisable at an exercise price of $1.30 per share beginning immediately after issuance and will expire five years from the date they are first exercisable, said the Waltham, Mass.-based genetic test maker.

Interleukin expects that its net proceeds will be $4.9 million after deducting placement agent fees and other offering expenses. It did not disclose its intended uses for the funds.

In early trade on the American Stock Exchange, shares of Interleukin tumbled 20 percent to $1.20. This follows yesterday's 16 percent increase in the share price, after Interleukin said that the results of a retrospective study suggest that individuals who base their diet on genotype could potentially benefit from the firm's weight management genetic test.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.